Dexmedetomidine for cancer pain: mechanisms and opioid-sparing effects
{{output}}
Background and objective: Cancer pain treatment faces challenges such as ineffective pain management, high-dose opioid use, and insufficient analgesia. Dexmedetomidine (DEX), a novel α2 receptor agonist, is a potential adjuvant ... ...
